Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2021-01-28 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F. The document includes a press release about manufacturing capacity expansion, but does not contain financial statements or detailed financial analysis. The document length is short (2185 characters), and it primarily serves as a regulatory filing to disclose material information. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and filings that do not fit other categories.
2021-01-28 English
SC 13G/A
Major Shareholding Notification
2021-01-15 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by RedHill Biopharma Ltd., which is a report of a foreign private issuer. The content includes a press release announcing the closing of a $25 million bought deal offering, describing the offering details, use of proceeds, and related information. There are no financial statements or detailed financial analysis present, only an announcement of a financing event. The document is about a capital raising transaction and does not contain an annual or interim report, audit report, or earnings release. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is over 11,000 characters, so it is not a brief announcement but a full filing of the financing update.
2021-01-14 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., with the SEC. It includes exhibits related to an amended underwriting agreement and legal opinions, which are typical for disclosures about financing or capital raising activities. The document is relatively short (2839 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or interim report, nor is it a transcript or management discussion. The presence of underwriting agreement and legal opinions strongly suggests this is related to capital or financing updates. Therefore, the document fits best under Capital/Financing Update (CAP).
2021-01-14 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of American Depositary Shares (ADSs) by RedHill Biopharma Ltd. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures. The presence of terms like 'prospectus supplement', 'offering', 'underwriting', and detailed share issuance information indicates this is a capital raising document. It is not an annual or quarterly report, earnings release, or management discussion. It is not a regulatory filing about voting, board changes, or legal proceedings. The document is a detailed offering prospectus supplement, which fits the category of Capital/Financing Update (CAP).
2021-01-13 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an increase in a previously announced bought deal offering of American Depositary Shares by RedHill Biopharma. It details the terms of the offering, the use of proceeds, and references the registration statement and prospectus filings with the SEC. There are no financial statements, management discussion, or detailed financial results presented. The document is primarily an update on a capital raising transaction and does not contain a full report or financial data. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and the content is consistent with a financing announcement rather than a regulatory filing or report publication announcement.
2021-01-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.